Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study.

Lv, Chao; Ma, Yuanyuan; Feng, Qin; Lu, Fangliang; Chi, Yongkun; Wu, Nan; Fang, Jian; Yang, Yue

Lv, Chao; Ma, Yuanyuan; Feng, Qin; Lu, Fangliang; Chi, Yongkun; Wu, Nan; Fang, Jian; Yang, Yue.

Afiliação

Lv C; Department of Thoracic Surgery II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Ma Y; Department of Thoracic Surgery II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Feng Q; Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Lu F; Department of Thoracic Surgery II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Chi Y; Department of Radiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Wu N; Department of Thoracic Surgery II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Fang J; Department of Thoracic Medical Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Yang Y; Department of Thoracic Surgery II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.

J Thorac Dis ; 12(10): 5324-5335, 2020 Oct.

Article em En | MEDLINE | ID: mdl-33209366

Palavras-chave

EGFR-tyrosine kinase inhibitor (EGFR-TKI) resistance; Epidermal growth factor receptor mutation (EGFR mutation); neoadjuvant TKI; next-generation sequencing (NGS); response rate

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies Idioma: En Revista: J Thorac Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China País de publicação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google